Zura Bio Limited (ZURA)
The price, the headline numbers and the latest news, in one place.
Zura Bio Limited (ZURA) Stock Price, Analysis & Data
| Bid | 4.09 |
| Market Cap | 563M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -116M |
| -0.03 | |
| -1.16 | |
| n/a | |
| -10.08 | |
| P/B (ttm) | 2.85 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 12, 2026 |
| Ask | 5.57 |
| Volume | 1,772,664 |
| Avg. Volume (20D) | 1,314,069 |
| Open | 5.58 |
| Previous Close | 5.67 |
| Day's Range | 5.50 - 5.94 |
| 52-Week Range | 1.88 - 7.44 |
| Analyst | n/a |
| Price Target | 18 (206.12%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobuli...
Financial Performance
In 2025, Zura Bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -68.65M, an increase of 31%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for ZURA stock is "null". The 12-month stock price forecast is 18, which is upside of 206.12% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.21 misses estimates by -0.02, with -23.53% YoY decline.
Analysts project revenue of ... Upgrade
